Alnylam Pharmaceuticals, Inc. - רווח נקי למניה אחת בשנים עשר החודשים האחרונים ALNY

Alnylam Pharmaceuticals (ALNY) possesses absolute pricing power due to the inelastic demand for the treatment of rare pathologies. This chart of net income per share YoY ttm demonstrates the inertia of the fundamental trend, where 6446.80 represents the latest metric reading. The high cost of therapy is driven by a lack of alternatives, while success is based on an innovative RNA interference platform that allows for the silencing of disease-causing genes.
Alnylam Pharmaceuticals - פילוחים אנליטיים ומדדי מפתח (ALNY)

This indicator calculates the percentage change in net income per share over a rolling twelve-month period. This metric determines the scaling rate of the business's real income, separating true growth from one-off factors. For Alnylam Pharmaceuticals (ALNY), which develops its own science through licensing alliances, earnings dynamics reflect the efficiency of RNA therapy commercialization. Analyzing the 12-month YoY EPS history allows for an assessment of whether the asset's current market value is justified.